Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Biogen Idec (NQ: BIIB )

157.90 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EST, Nov 22, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Biogen Idec

< Previous 1 2
...
14 15 16 17 18 19 20 21 22
...
48 49 Next >
These Analysts Revise Price Targets On Biogen Following Q1 Results
Biogen Inc. (NASDAQ: BIIB) reported results for its first quarter. 
Via Benzinga
FDA Grants Accelerated Approval for QALSODY™ (tofersen) for SOD1-ALS, a Major Scientific Advancement as the First Treatment to Target a Genetic Cause of ALS
From Biogen Inc.
Via GlobeNewswire
What's Going On With Biogen Stock Tuesday?
Biogen Inc (NASDAQ: BIIB) shares are trading lower Tuesday. The company reported first-quarter results before the bell and the FDA approved its ALS therapy Tuesday afternoon.  
Via Benzinga
Biogen On The Hunt
Biogen is in the process of culling its pipeline to prepare for its upcoming deal making. What is happening and what does it mena? 
Via Talk Markets
Biogen Inc. Beats Q1 Earnings And Revenue Estimates
Biogen Inc. came out with quarterly earnings of $3.40 per share. 
Via Talk Markets
Earnings Outlook For Biogen
Via Benzinga
What Does Biogen's Debt Look Like?
Via Benzinga
P/E Ratio Insights for Biogen
Via Benzinga
Is Biogen Stock a Buy Now?
The company's fascinating saga in the Alzheimer's disease drug market continues. 
Via The Motley Fool
Biogen Announces Additional Cost Cutting Initiatives, Chops Certain Stroke, Gene Therapy Programs
Via Benzinga
Alzheimer's Drugs Still Aren't Biogen's Saving Grace — But The Company Is Hopeful
The company is hopeful for maintenance dosing and a new injection of the drug. 
Via Investor's Business Daily
3 Top Biotech Stocks Defying the Bear Market
All three companies have therapies with strong sales potential. 
Via The Motley Fool
Why Legend Biotech Stock Is Having Its Best Month Yet
With the biotech market’s focus back on treatments for cancer and other life-threatening diseases, Legend has now tripled off its bottom to a record high. 
Via MarketBeat
Why Shares of Keros Therapeutics Jumped This Week
The company appointed a new director and an analyst reiterated his position on the stock. 
Via The Motley Fool
Leqembi Sales To Propel Biogen Stock To New Heights, Says Bullish Analyst
Via Benzinga
Biogen Earnings Conference Call Is Coming Up, Here's What You Need To Know
Via Benzinga
12 Analysts Have This to Say About Biogen
Via Benzinga
Biogen To Report Q1 Earnings: Here's What To Expect
We expect Biogen to beat expectations when it reports first-quarter 2023 results on Apr. 25 before the market opens. In the last reported quarter, the company delivered an earnings surprise of 15.38%. 
Via Talk Markets
Will US Medicare Fully Cover Alzheimer's Drugs? Eli Lilly Thinks Yes!
Eli Lilly And Co (NYSE: LLY) expects the U.S. Medicare health plan to loosen its grip on the coverage limits on new Alzheimer's drugs, as more data emerging in coming weeks show that clearing amyloid... 
Via Benzinga
Better Big Biotech Buy: Biogen vs. Vertex
One is slightly cheaper than the other. 
Via The Motley Fool
Cancer And Diabetes Remain Among The Deadliest And Most Debilitating Diseases — Is Gene Therapy The Solution? One Company, Genprex, Inc. (NASDAQ: GNPX), Thinks So
On their own, cancer or diabetes can be debilitating and deadly. The two are common diseases with tremendous impact on health worldwide. 
Via Benzinga
3 Stocks to Buy That Could Be the Next Biotech Breakthrough
Biotech stocks are highly speculative, but it's possible to choose ones with excellent risk-reward ratios. 
Via InvestorPlace
Benzinga's Top Ratings Upgrades, Downgrades For April 17, 2023
Via Benzinga
7 Sorry Pharma Stocks to Sell in April Before It’s Too Late
You have to be patient when investing in pharma stocks. But sometimes the risk and the wait aren't worth the rewards. 
Via InvestorPlace
Biogen Moves Deeper In Alzheimer's With Denali
Biogen exercised their rights to a Denali Alzheimer's drug. What does this mean longer term to the field and the companies? 
Via Talk Markets
The Unexpected Way The Texas Abortion Ruling Could Destroy Biotech
One executive called this the most "damaging" decision in five decades. 
Via Investor's Business Daily
New York and California Prepare For Potential Mifepristone Ban In Texas With Stockpiling Of Alternative Abortion Medications
New York and California are stockpiling an alternative abortion medication in case a Texas judge's order suspending the FDA approval of the primary drug, mifepristone, goes into effect later this... 
Via Benzinga
Biogen Exercises Option with Denali to Develop and Commercialize Antibody Transport Vehicle Program Targeting Amyloid Beta
Program uses Denali’s Antibody Transport Vehicle (ATV) technology to cross the blood-brain barrier (BBB) and aims to increase target engagement 
From Denali Therapeutics Inc.
Via GlobeNewswire
Attorney Generals of Over 20 States Sound Alarm Over Suspension Of Abortion Med Approval: "Devastating Risks" Ahead
In a new court filing, the Democratic attorneys general for 23 U.S. states have reportedly warned that a federal judge's decision to suspend the FDA's approval of mifepristone "presents devastating... 
Via Benzinga
3 Biotech Stocks to Watch for Potential Breakthroughs
These biotech stocks have significant upside and realistic breakthrough chances in the current and distant future. 
Via InvestorPlace
< Previous 1 2
...
14 15 16 17 18 19 20 21 22
...
48 49 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.